Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Front Oncol. 2020 Jul 10:10:1223. doi: 10.3389/fonc.2020.01223. eCollection 2020.

Serena Di Cosimo¹, Luca Porcu², Andrea Malfettone³, Javier Cortés^{3

4

5

6

7}, Rosalba Miceli⁸

¹ Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
² Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
³ Medica Scientia Innovation Research (MedSIR), New Jersey, United States.
⁴ Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
⁵ IOB Institute of Oncology, Quiron Group, Madrid, Spain.
⁶ IOB Institute of Oncology, Quiron Group, Barcelona, Spain.
⁷ Vall d'Hebron Insititute of Oncology (VHIO), Barcelona, Spain.
⁸ Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

No abstract available

Keywords: COVID-19; SARS-CoV-2 infection; cancer care; patient guidance; risk factors.

Publication types